Jazz Pharmaceuticals' rare liver disorder drug wins U.S. approval

March 30, 2016 4:29 PM

16 0

The U.S. Food and Drug Administration has cleared Jazz Pharmaceuticals Plc's drug to treat a rare kind of liver disease, making it the first treatment to win U.S. approval for the condition.

The drug, defibrotide, targets patients with hepatic veno-occlusive disease (VOD), a condition in which some of the veins in the liver become blocked, causing swelling and a decrease in blood flow inside the liver, leading to liver damage.

Also read: National Cancer Institute Says Researchers Didn’t Quickly Tell FDA After Two Deaths in a Lymphoma Study

Read more

To category page